CD274 and cancer: This regulatory approval opens a door to the entry of more promising LAG-3 targeting molecules in the clinical practice market, and to an extension of Opdualag indications to other malignancies, supporting the accumulating evidence that indicates that LAG-3 will play a pivotal role in cancer treatment equivalent to current anti-PD-1/anti-PD-L1 treatments.